الوصف
Summary analysis from the GTB1 probiotic trial showing the relationship between gut microbiota modulation and IBS-D symptom outcomes. The findings support the potential role of Lactiplantibacillus plantarum in managing diarrhea-predominant IBS through microbiome modification.
Figure 18
ChartSource Paper
Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.Cite This Figure
![Figure 18: Summary analysis from the GTB1 probiotic trial showing the relationship between gut microbiota modulation and IBS-D symptom outcomes. The findings support the potential role of Lactiplantibacillus plantarum in managing diarrhea-predominant IBS through microbiome modification.]() > Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." *Nutrients*, 2022. PMID: [35631156](https://pubmed.ncbi.nlm.nih.gov/35631156/)
<figure> <img src="" alt="Summary analysis from the GTB1 probiotic trial showing the relationship between gut microbiota modulation and IBS-D symptom outcomes. The findings support the potential role of Lactiplantibacillus plantarum in managing diarrhea-predominant IBS through microbiome modification." /> <figcaption>Figure 18. Summary analysis from the GTB1 probiotic trial showing the relationship between gut microbiota modulation and IBS-D symptom outcomes. The findings support the potential role of Lactiplantibacillus plantarum in managing diarrhea-predominant IBS through microbiome modification.<br> Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35631156/">35631156</a></figcaption> </figure>